prikaz prve stranice dokumenta Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
  Preuzmi
PDF 946.74 KB
Znanstveni rad - Pregledni rad
Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
Pharmaceutics, 13 (2021), 9; 1481. https://doi.org/10.3390/pharmaceutics13091481
Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis

Povezani objekti
COVID-19 | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Primorac, D., Čemerin, M., Matišić, V., Molnar, V., Strbad, M., Girandon, L. ... Polančec, D. (2021). Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics, 13. (9). doi: 10.3390/pharmaceutics13091481

Primorac, Dragan, et al. "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment." Pharmaceutics, vol. 13, br. 9, 2021. https://doi.org/10.3390/pharmaceutics13091481

Primorac, Dragan, Martin Čemerin, Vid Matišić, Vilim Molnar, Marko Strbad, Lenart Girandon, Lucija Zenić, Miomir Knežević, Stephen Minger i Denis Polančec. "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment." Pharmaceutics 13, br. 9 (2021). https://doi.org/10.3390/pharmaceutics13091481

Primorac, D., et al. (2021) 'Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment', Pharmaceutics, 13(9). doi: 10.3390/pharmaceutics13091481

Primorac D, Čemerin M, Matišić V, Molnar V, Strbad M, Girandon L, i sur.. Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics [Internet]. 16.09.2021. [pristupljeno 13.05.2024.];13(9). doi: 10.3390/pharmaceutics13091481

D. Primorac, et al., "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment", Pharmaceutics, vol. 13, br. 9, Rujan 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:165701. [Citirano: 13.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:165701
Podaci o radu
Naslov (engleski)Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
AutorDragan Primorac
AutorMartin Čemerin
AutorVid Matišić
AutorVilim Molnar
AutorMarko Strbad
AutorLenart Girandon
AutorLucija Zenić
AutorMiomir Knežević
AutorStephen Minger
AutorDenis Polančec
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmaceutics
Brojčani podacivol. 13, br. 9, 1481
e-ISSN1999-4923
DOIhttps://doi.org/10.3390/pharmaceutics13091481
URN:NBNurn:nbn:hr:184:165701
Datum objave publikacije2021-09-16
URL dokumentahttps://www.mdpi.com/1999-4923/13/9/1481
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-12-03 11:26:40